Latest H5N1 clinical trials Stories

Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac's RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection

2012-11-25 12:20:14

TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases. In vivo data published by...

BiondVax is Declared "A Good Manufacturing Practice (GMP) Company" After Passing European Qualified Person (QP) Audit; BiondVax Signs Agreement to Collaborate With MonoSol on Developing Oral Delivery for Universal Flu Vaccine M-001

2012-10-22 11:25:37

NES ZIONA, Israel, October 22, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) today announced that the Company has passed successfully a 2 day QP GMP audit during which the Company`s manufacturing facility, production process, personnel and quality control procedures were examined in great detail. This demanding certification is a requirement for Companies intending to manufacture a clinical grade product for human trials anywhere in Europe and gives the...

Sanofi Pasteur Presents Phase III Data for Investigational Quadrivalent Influenza Vaccine

2012-10-22 07:30:26

SWIFTWATER, Pa., Oct. 22, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV). Three clinical trials have been conducted to evaluate the safety and the immune response to the quadrivalent influenza vaccine in children, adults and the elderly. All three studies demonstrated that the safety and immunogenicity...

Sanofi Pasteur Announces Application for New Four-Strain Influenza Vaccine Accepted by FDA for Review

2012-10-18 07:26:23

SWIFTWATER, Pa., Oct. 18, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone(® ) (Influenza Virus Vaccine). The sBLA file has been accepted by the FDA for full review, and an action date is anticipated in the second quarter of 2013. "The...

Pfenex Inc. Awarded Contract by the National Institute of Allergy and Infectious Diseases (NIAID) to Develop an Alternative Delivery Method for its Recombinant Protective Antigen (rPA)-based Anthrax Vaccine

2012-10-17 07:27:45

SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) under its Broad Agency Announcement entitled "Vaccine Technologies to Advance Next Generation Anthrax Vaccines" (BAA-NIAID-DMID-NIHAI2010104) has awarded Pfenex a contract to develop an alternative delivery method for Pfenex's recombinant Protective Antigen (rPA)-based anthrax vaccine. NIAID, part of the National Institutes of Health, has made an...

Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine

2012-09-05 22:22:21

BLUE BELL, Pa., Sept. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the interim analysis of its SynCon® universal H1N1 influenza vaccine showed that it generated protective HAI titers against some of the most prevalent strains of H1N1 influenza from the past 100 years in a phase I clinical trial. Because the SynCon® approach incorporates sequence information from multiple divergent strains, the vaccine is not matched to any of the...

Scientists Find Compound That Helps HIV, Flu Vaccines

2012-08-27 11:50:37

Novel vaccine additive to enhance the body's immune response shows promise in mice Oxford University scientists have discovered a compound that greatly boosts the effect of vaccines against viruses like flu, HIV and herpes in mice. An 'adjuvant' is a substance added to a vaccine to enhance the immune response and offer better protection against infection. The Oxford University team, along with Swedish and US colleagues, have shown that a type of polymer called polyethyleneimine (PEI)...

GlaxoSmithKline shipping U.S. flu vaccine with new strain coverage recommended for 2012-2013

2012-07-31 06:25:58

PHILADELPHIA, July 31, 2012 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] announced today it has begun shipping the first lots of 2012-2013 FluLaval®( )(Influenza virus vaccine) and Fluarix® (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This follows approval of this season's GSK seasonal influenza vaccines by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research. FLULAVAL is approved for use in adults (18 years of...

Deadly Poultry Virus Caused By Gene-Swapping Vaccines

2012-07-13 10:37:54

Brett Smith for redOrbit.com - Your Universe Online Australian scientists looking to vaccinate chicken populations against a respiratory disease may have accidentally unleashed a disease far more deadly than the one they hoped to prevent. According to a report published this week in Science, the genomes from two different strains of the herpesvirus infectious laryngotracheitis (ILT) virus that were used in vaccines have recombined to produce more virulent ILT viruses near Sydney and...

iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform

2012-06-18 02:26:53

NEWARK, Del., June 18, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that the US Patent Office has allowed patent application 11/706,576 entitled "Bacillus anthracis Antigens, Vaccine Compositions, and Related Methods." The claims cover compositions and methods for fusions of sequences of Bacillus anthracis antigens for protective antigen (PA), lethal factor (LF), and edema factor (EF), and combinations thereof to LicKM, which is part of the Company's...